GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zhaoke Ophthalmology Ltd (HKSE:06622) » Definitions » YoY EBITDA Growth

Zhaoke Ophthalmology (HKSE:06622) YoY EBITDA Growth : -4.07% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Zhaoke Ophthalmology YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Zhaoke Ophthalmology's YoY EBITDA Growth for the quarter that ended in Dec. 2024 was -4.07%.

Zhaoke Ophthalmology's EBITDA per Share for the six months ended in Dec. 2024 was HK$-0.31.

Zhaoke Ophthalmology YoY EBITDA Growth Historical Data

The historical data trend for Zhaoke Ophthalmology's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhaoke Ophthalmology YoY EBITDA Growth Chart

Zhaoke Ophthalmology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EBITDA Growth
Get a 7-Day Free Trial -623.61 -299.30 87.82 13.29 48.25

Zhaoke Ophthalmology Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -57.68 -33.91 41.35 69.70 -4.07

Zhaoke Ophthalmology YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Zhaoke Ophthalmology's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (A: Dec. 2024 )
=(EBITDA per Share (A: Dec. 2024 )-EBITDA per Share (A: Dec. 2023 ))/ | EBITDA per Share (A: Dec. 2023 ) |
=(-0.341--0.659)/ | -0.659 |
=48.25 %

Zhaoke Ophthalmology's YoY EBITDA Growth for the quarter that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (Q: Dec. 2024 )
=(EBITDA per Share (Q: Dec. 2024 )-EBITDA per Share (Q: Dec. 2023 )) / | EBITDA per Share (Q: Dec. 2023 )) |
=(-0.307--0.295)/ | -0.295 |
=-4.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhaoke Ophthalmology YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Zhaoke Ophthalmology's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhaoke Ophthalmology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zhaoke Ophthalmology Ltd (HKSE:06622) » Definitions » YoY EBITDA Growth
Comparable Companies
HKSE:02496 HKSE:01244 HKSE:02511 HKSE:06998 HKSE:02898 HKSE:02126 HKSE:02185 HKSE:06628 HKSE:09939 HKSE:02137 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
9FX:Germany
Address
No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangdong Province, Guangzhou, CHN
Website
https://www.zkoph.com
Zhaoke Ophthalmology Ltd is an ophthalmic pharmaceutical company. It is dedicated to the research, development, and commercialization of therapies that address unmet medical needs in China. The company has built a comprehensive ophthalmic drug pipeline of 26 candidates that covers ocular indications affecting the front and the back of the eye, through either in-house development or in-licensing. It has also established an ophthalmic manufacturing facility and is assembling an experienced marketing team in anticipation of a near-term product launch.
Executives
Mak Siu Hang Viola 2201 Interest of corporation controlled by you
Gic Private Limited 2201 Interest of corporation controlled by you
Apstar Investment Pte Ltd 2201 Interest of corporation controlled by you
Coyote Investment Pte Ltd 2101 Beneficial owner
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Fidelity China Special Situations Plc 2101 Beneficial owner
Fil Limited 2201 Interest of corporation controlled by you
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
Citigroup Inc. 2502 Approved lending agent
Vms Holdings Limited 2201 Interest of corporation controlled by you
Lee's Pharmaceutical Holdings Limited 2201 Interest of corporation controlled by you
Tpg Asia Genpar Vii, L.p. 2201 Interest of corporation controlled by you
Tpg Holdings Iii-a, L.p. 2201 Interest of corporation controlled by you

Zhaoke Ophthalmology Headlines

No Headlines